With a key parliamentary committee preparing to vote on revisions to the EU’s pharmaceutical legislation, European R&D-based industry group EFPIA has reiterated its concerns over a proposal to slice two years off the baseline period of regulatory data protection (RDP) in an effort to foster earlier generic and biosimilar competition.
As Vote Nears, EFPIA Chief Sounds The Alarm Over Data Protection Cuts
Nathalie Moll says that the European Commission’s estimates of the costs to EU member states of regulatory data protection are “incorrect and over-estimated.”
